Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Sorbonne Université doctoral scolarship INSERM Introduction Brugada syndrome (BrS) is an inherited cardiac arrhythmia that greatly increases the risk of sudden death as a result of ventricular fibrillation. Approximately 20% of BrS cases can be attributed to a mutation in SCN5A, the gene encoding the alpha-subunit Nav1.5 of the cardiac sodium-channel, which carries the sodium current INa. These mutations typically lead to loss-of-function of Nav1.5, resulting in a decrease in INa and most of them (»70 %) are responsible for haploinsufficiency. In the Scn5a+/- mouse model, a sodium-channel dysfunction phenotype is observed, characterized by conduction abnormalities (PR and QRS interval prolongation), a 50% reduction in INa, and an increased susceptibility to arrhythmias. Aim The aim of this study was to assess the impact of the overexpression of a Nav1.5-peptide, which has been found to enhance INa, in Scn5a+/- mice, as a novel approach of therapy. Methods We used AAV9-systemic injection to overexpress the Nav1.5-peptide into the heart of Scn5a+/- mice to gauge their susceptibility to arrhythmias induced by intracardiac pacing. We also examined the Nav1.5-peptide effects on endogenous Nav1.5 expression through molecular biology and biochemistry analyses. Results The duration of PR and QRS intervals in the hearts of Scn5a+/- mice was restored to normal by overexpression of the Nav1.5-peptide (PR interval = 46.3 ± 0.9 ms, n=22 in Scn5a+/- mice vs 40.4 ± 0.8 ms, n= 23 in WT mice, P<0.0001 and 42.6 ± 0.9 ms, n=11 in Scn5a+/- +Nav1.5-peptide, P<0.05; QRS interval = 15.2 ± 0.4, n=22 ms in Scn5a+/- mice vs 13.2 ± 0.4 ms, n=23 in WT mice, P<0.01 and 13.6 ± 0.4 ms, n=14 in Scn5a+/- +Nav1.5-peptide, P<0.05). Additionally, overexpression of the Nav1.5-peptide seemed to protect Scn5a+/- mice from induced arrhythmic events caused by programmed-ventricular stimulation (total premature beats = 1.3 ± 0.4 in Scn5a+/- mice, n = 13 vs 0.2 ± 0.2, n = 6 in injected Scn5a+/- mice, NS and 0.2 ± 0.2, n = 12 in WT mice, P< 0.05). There were no significant differences in total Nav1.5 expression between injected and non-injected mice as shown by RT-qPCR and Western-blots, but the expression of Nav1.5 at the plasma membrane appeared to be restored by overexpression of the Nav1.5-peptide (Nav1.5/N-cadherin ratio = 0.50 ± 0.08, n = 11 in Scn5a+/- mice vs 1 ± 0.15, n= 11 in WT mice, P< 0.05 and 0.94 ± 0.13, n = 11 in injected Scn5a+/- mice, P< 0.05). Conclusion Gene therapy with Nav1.5-peptide can attenuate both conduction defects and increased arrhythmia inducibility observed in Scn5a+/- mice. Although additional studies will be needed to confirm and explore further our results, this could be promising to treat patients with « sodium-channel dysfunction » such as BrS.

Arrhythmic Substrate, Slowed Propagation and Increased Dispersion in Conduction Direction in the Right Ventricular Outflow Tract of Murine Scn5a+/- Hearts

Increased Right Ventricular Repolarization Gradients Promote Arrhythmogenesis In A Murine Model Of Brugada Syndrome

Delayed Conduction and Its Implications in Murine Scn5a +/− Hearts: Independent and Interacting Effects of Genotype, Age, and Sex

Atrial Arrhythmogenic Properties In Wild-Type And Scn5a+/- Murine Hearts

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

In Vivo Studies of Scn5a+/− Mice Modeling Brugada Syndrome Demonstrate Both Conduction and Repolarization Abnormalities

Experimental Physiology –research Paper: Atrial Arrhythmogenic Properties in Wild‐type and Scn5a+/− Murine Hearts

Frequency distribution analysis of activation times and regional fibrosis in murine Scn5a+/- hearts: the effects of ageing and sex.

Altered Sinoatrial Node Function and Intra-Atrial Conduction in Murine Gain-of-function Scn5a+/ΔKPQ Hearts Suggest an Overlap Syndrome

The Age‐dependence of Atrial Arrhythmogenicity in Scn5a+/−murine Hearts Reflects Alterations in Action Potential Propagation and Recovery

The RyR2-P2328S Mutation Downregulates Nav1.5 Producing Arrhythmic Substrate in Murine Ventricles

In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant

Study of the cardiac sodium channel in a mouse model of Scn5a haploinsufficiency towards a novel approach of therapy

Pathophysiological Mechanisms of Sino-Atrial Dysfunction and Ventricular Conduction Disease Associated with SCN5A Deficiency: Insights from Mouse Models

Altered firing activity of intracardiac neurons isolated from mice carrying the Scn5a-1798insD mutation

The Relationship Between Conduction Velocity and Atrial Arrhythmogenicity under Conditions of Altered Ca2+Homeostasis in Ryr2-P2328s Murine Hearts

Variant Intronic Enhancer Controls SCN10A-short Expression and Heart Conduction

Atrial Arrhythmogenesis in Wild-Type and Scn5a+/Δ Murine Hearts Modelling LQT3 Syndrome

Atrial Arrhythmogenicity in Aged Scn5a+/∆KPQ Mice Modeling Long QT Type 3 Syndrome and Its Relationship to Na+ Channel Expression and Cardiac Conduction

Prolongation of atrio-ventricular node conduction in a rabbit model of ischaemic cardiomyopathy: Role of fibrosis and connexin remodelling

Atrial Arrhythmia, Triggering Events and Conduction Abnormalities in Isolated Murine Ryr2-P2328s Hearts